Select Publications
Attal M et al. Maintenance treatment with lenalidomide after transplantation for myeloma: Analysis of secondary malignancies within the IFM 2005-02 trial. Proc International Myeloma Workshop 2011. Abstract
Davies FE et al. Are there benefits to long-term bisphosphonate treatment in multiple myeloma (MM)? Insights from temporal analyses of zoledronic acid (ZOL) versus clodronate (CLO) in the MRC Myeloma IX trial. Proc ASCO 2011;Abstract 8011.
Harousseau JL et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: Results of the IFM 2005-01 phase III trial. J Clin Oncol 2010;28(30):4621-9. Abstract
Jakubowiak AJ et al. Final results of a frontline phase 1/2 study of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) in multiple myeloma (MM). Proc ASH 2011;Abstract 631.
Lacy MQ et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: Comparison of 2 dosing strategies in dual-refractory disease. Blood 2011;118(11):2970-5. Abstract
Lonial S et al. Up-front management of multiple myeloma. Oncology 2010;24(12 Suppl 5):8-14. No abstract available
Love N et al. Tolerance and response to initial systemic therapy in older patients with multiple myeloma (MM): Observations from 276 unselected recent cases in the practices of US-based medical oncologists (MOs). Proc ASH 2010;Abstract 1516.
McCarthy P et al. Phase III Intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB ECOG BMT-CTN 100104. Proc International Myeloma Workshop 2011. Abstract
Moreau P et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: A randomised, phase 3, non-inferiority study. Lancet Oncol 2011;12(5):431-40. Abstract
Moreau P et al. A phase 3 prospective randomized international study (MMY-3021) comparing subcutaneous and intravenous administration of bortezomib in patients with relapsed multiple myeloma. Proc ASH 2010;Abstract 312.
Palumbo A et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: A report of the European Myeloma Network (EMN). Blood 2011;118:4519-29. Abstract
Palumbo A et al. A phase III study of VMPT versus VMP in newly diagnosed elderly myeloma patients. Proc ASCO 2009;Abstract 8515.
Palumbo A et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: A randomized controlled trial. J Clin Oncol 2010;28(34):5101-9. Abstract
Rajkumar SV et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: An open-label randomised controlled trial. Lancet Oncol 2010;11(1):29-37. Abstract
Randomized study comparing conventional dose treatment using a combination of lenalidomide, bortezomib and dexamethasone to high-dose treatment with ASCT in the initial management of myeloma in patients up to 65 years of age. NCT01191060
Richardson PG et al. Randomized, open label phase 1/2 study of pomalidomide (POM) alone or in combination with low-dose dexamethasone (LoDex) in patients (pts) with relapsed and refractory multiple myeloma who have received prior treatment that includes lenalidomide (LEN) and bortezomib (BORT): Phase 2 results. Proc ASH 2011;Abstract 634.
Richardson PG et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010;116(5):679-86. Abstract
Siegel D et al. PX-171-003-A1, an open-label, single-arm, phase (Ph) II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (R/R MM): Long-term follow-up and subgroup analysis. Proc ASCO 2011;Abstract 8027.
Vij R et al. PX-171-004, a multicenter phase II study of carfilzomib (CFZ) in patients with relapsed myeloma: An efficacy update. Proc ASCO 2009;Abstract 8537.